Lebwohl, Mark, Hervé Bachelez, Kenneth Gordon, Tianshuang Wu, Michael Chen, Blair Kaplan, and Kim Papp. “Maintenance of Clinical Response With Continued Risankizumab Treatment for Moderate-to-Severe Psoriasis Through 304 Weeks: Interim Analysis of the LIMMitless Open-Label Extension Study”. SKIN The Journal of Cutaneous Medicine 7, no. 6 (November 13, 2023): s258. Accessed July 3, 2024. https://jofskin.org/index.php/skin/article/view/2428.